Who are Risperidone, Haloperidol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): quetiapine (Seroquel) XR, Risperdal,reminyl, quetiapine fumarate vs risperidone, Quetiapine Immediate Release, placebo with Clozapine, full-dose olanzapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/risperidone-haloperidol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Risperidone, Haloperidol — Competitive Intelligence Brief

Risperidone, Haloperidol (Risperidone, Haloperidol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic. Area: Psychiatry/Neurology.

marketed Antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Risperidone, Haloperidol (Risperidone, Haloperidol) — Ludwig-Maximilians - University of Munich. Risperidone and haloperidol are antipsychotic medications that block dopamine and serotonin receptors in the brain to reduce psychotic symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Risperidone, Haloperidol TARGET	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
quetiapine (Seroquel) XR	quetiapine (Seroquel) XR	Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Risperdal,reminyl	Risperdal,reminyl	Jinan Mental Hospital	marketed	Atypical antipsychotic (Risperdal); Cholinesterase inhibitor (Reminyl)	Dopamine D2 receptor, serotonin 5-HT2A receptor (Risperdal); Acetylcholinesterase (Reminyl)
quetiapine fumarate vs risperidone	quetiapine fumarate vs risperidone	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine Immediate Release	Quetiapine Immediate Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
placebo with Clozapine	placebo with Clozapine	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
full-dose olanzapine	full-dose olanzapine	Kaohsiung Kai-Suan Psychiatric Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipsychotic class)

Fundación Pública Andaluza Progreso y Salud · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Technical University of Munich · 1 drug in this class
University of Utah · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Risperidone, Haloperidol — Competitive Intelligence Brief. https://druglandscape.com/ci/risperidone-haloperidol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab